How Patient Characteristics, SDOH, Impact CLL, SLL Treatment Backdrop
Social determinants of health (SDOH), such as financial disparities or lack of insurance, create barriers to accessing breakthrough therapies like BTK inhibitors among patients with CLL and SLL.
Assessing B-Cell Maturation Antigen Directed Therapies in Multiple Myeloma Treatment
Three posters presented at the 65th American Society of Hematology Annual Meeting and Exposition looked into the efficacy and safety of the therapies.
Evaluating Multiple Myeloma Survival Rates by Race, Ethnicity, and Rural-Urban Location
Data from the Surveillance, Epidemiology, and End Results (SEER) database were reviewed.
Slideshow: Examining the Treatment Landscape for Chronic Lymphocytic Leukemia
Six posters presented at the 65th American Society of Hematology Annual Meeting and Exposition looked at how treatments are impacting care for this patient population.
Understanding Adverse Events With BCMA-, Non-BCMA-Targeting Bispecific Antibodies in Multiple Myeloma
Understanding the adverse event profile of bispecific antibodies can aid treatment selection and improve patient outcomes.
Daratumumab Plus VRd Improves Progression Free Survival in Newly Diagnosed Multiple Myeloma
Results of the phase 3 PERSEUS study were presented at the 2023 ASH Annual Meeting and Exposition.
2 Commerce Drive Cranbury, NJ 08512